218151-53-2

Basic information

• Product Name: BOC-(1S,2R)-(-)-CIS-1-AMINO-2-INDANOL
• Synonyms: BOC-(1S,2R)-(-)-CIS-1-AMINO-2-INDANOL;(1S,2R)-N-BOC-1-AMINO-2-INDANOL;(1S,2R)-1-(Boc-amino)-2-indanol
• CAS NO: 218151-53-2
• Molecular Formula: C₁₄H₁₉NO₃
• Molecular Weight: 249.31
• Mol File: 218151-53-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BOC-(1S,2R)-(-)-CIS-1-AMINO-2-INDANOL(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-(1S,2R)-(-)-CIS-1-AMINO-2-INDANOL(218151-53-2)
• EPA Substance Registry System: BOC-(1S,2R)-(-)-CIS-1-AMINO-2-INDANOL(218151-53-2)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 218151-53-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7480-35-5 (1S,2R)-1-amino-2-indanol 
• 403860-45-7 tert-butyl N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamate 
• 136030-00-7 (1R,2S)-1-Amino-2-indanol 
• 1104640-90-5 t-butyl 3-nitro-1H-1,2,4-triazole-1-carboxylate 
• 766556-65-4 (1R, 2R)-4-nitro-benzoic acid 1-tert-butoxycarbonylamino-indan-2-yl ester 
• 97-72-3 2-Methylpropionic anhydride 

Downstream Products

• 218151-47-4 (1S,2S)-trans-1,2-diaminoindane 
• 438051-03-7 tert-butyl ((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)carbamate 
• 218151-54-3 Toluene-4-sulfonic acid (1S,2R)-1-tert-butoxycarbonylamino-indan-2-yl ester 

Relevant articles and documents

Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists

Cachexia and muscle wasting are very common among patients suffering from cancer, chronic obstructive pulmonary disease, and other chronic diseases. Ghrelin stimulates growth hormone secretion via the ghrelin receptor, which subsequently leads to increase of IGF-1 plasma levels. The activation of the GH/IGF-1 axis leads to an increase of muscle mass and functional capacity. Ghrelin further acts on inflammation, appetite, and adipogenesis and for this reason was considered an important target to address catabolic conditions. We report the synthesis and properties of an indane based series of ghrelin receptor full agonists; they have been shown to generate a sustained increase of IGF-1 levels in dog and have been thoroughly investigated with respect to their functional activity.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral gp120 receptor (e.g., temsavir, BMS-818251, DMJ-ll-121, BNM-IV-147, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin- binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., HIV infections).

Catalyst-Controlled Regioselective Chlorination of Phenols and Anilines through a Lewis Basic Selenoether Catalyst

We report a highly efficient ortho-selective electrophilic chlorination of phenols utilizing a Lewis basic selenoether catalyst. The selenoether catalyst resulted in comparable selectivities to our previously reported bis-thiourea ortho-selective catalyst, with a catalyst loading as low as 1%. The new catalytic system also allowed us to extend this chemistry to obtain excellent ortho-selectivities for unprotected anilines. The selectivities of this reaction are up to >20:1 ortho/para, while the innate selectivities for phenols and anilines are approximately 1:4 ortho/para. A series of preliminary studies revealed that the substrates require a hydrogen-bonding moiety for selectivity.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

Synthesis of chiral aminophosphines from chiral aminoalcohols via cyclic sulfamidates

(Chemical Equation Presented) Protic aminophosphines with multiple chiral centers were synthesized in good yields and high purity by the nucleophilic ring-opening of N-protected cyclic sulfamidates with metal phosphides, followed by hydrolysis and deprote

Enantioselective heterocyclic synthesis of spiro chromanone-thiochroman complexes catalyzed by a bifunctional indane catalyst

Novel asymmetric domino reactions of benzylidenechroman-4-ones and 2-mercaptobenzaldehydes for efficient construction of spiro chromanone- thiochroman complexes were accomplished with high yields and excellent selectivities via a novel bifunctional indane

Enantioselective synthesis of densely functionalized pyranochromenes via an unpredictable cascade Michael-oxa-Michael-tautomerization sequence

A surprising example of enantioselective cascade Michael-oxa-Michael- tautomerization reactions of malononitrile and benzylidenechromanones has been developed. In this case, malononitrile functions as both nucleophile and electrophile. Meanwhile, a simple

Development of column-free alkoxycarbonyl, aryloxycarbonyl, and acyl transfer reagents

Easy-to-handle alkoxycarbonyl, aryloxycarbonyl, and acyl transfer reagents, which contain 3-nitro-1,2,4-triazole (NT) as a leaving group, were developed. With these reagents (NT reagents), which are stable nonhygroscopic crystalline materials, the reactions can be accomplished in about 5 min, and product can be isolated without tedious column chromatographic purification.

METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS

The present application is directed to i) a two-step method for synthesizing phosphme-ammophosphme (P,N,P) ligands, ii) the use of such ligands in the preparation of metal complexes as hydrogenation catalysts, and iii) ammophosphme (P,N) and phosphme-ammo

Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications

We previously reported a series of enantiopure cis-(1R,2S)-cyclopentyldiamine derivatives as potent and selective inhibitors of Factor Xa (FXa). Herein, we describe our approach to improve the metabolic stability of this series via core modifications. Multiple resulting series of compounds demonstrated similarly high FXa potency and improved metabolic stability in human liver microsomes compared with the cyclopentyldiamide 1. (3R,4S)-Pyrrolidinyldiamide 31 was the best overall compound with human FXa Ki of 0.50 nM, PT EC2x of 2.1 μM in human plasma, bioavailability of 25% and t1/2of 2.7 h in dogs. Further biochemical characterization of compound 31 is also presented.